121 related articles for article (PubMed ID: 28111468)
1. Deletion of Ptpn1 induces myeloproliferative neoplasm.
Jobe F; Patel B; Kuzmanovic T; Makishima H; Yang Y; Przychodzen B; Hutchison RE; Bence KK; Maciejewski JP; Mohi G
Leukemia; 2017 May; 31(5):1229-1234. PubMed ID: 28111468
[No Abstract] [Full Text] [Related]
2. 7q22 deletion in myeloid malignancies: be attentive to the design of the FISH probe.
Struski S; Luquet I
Ann Biol Clin (Paris); 2019 Apr; 77(2):229-230. PubMed ID: 30907375
[No Abstract] [Full Text] [Related]
3. Prognostic significance of del(20q) in patients with hematological malignancies.
Brezinová J; Zemanová Z; Ransdorfová S; Sindelárová L; Sisková M; Neuwirtová R; Cermák J; Michalová K
Cancer Genet Cytogenet; 2005 Jul; 160(2):188-92. PubMed ID: 15993278
[TBL] [Abstract][Full Text] [Related]
4. Chromosome 20 deletions in myelodysplastic syndromes and Philadelphia-chromosome-negative myeloproliferative disorders: characterization by molecular cytogenetics of commonly deleted and retained regions.
Douet-Guilbert N; Basinko A; Morel F; Le Bris MJ; Ugo V; Morice P; Berthou C; De Braekeleer M
Ann Hematol; 2008 Jul; 87(7):537-44. PubMed ID: 18350294
[TBL] [Abstract][Full Text] [Related]
5. Genomic analysis of clonal eosinophils by CGH arrays reveals new genetic regions involved in chronic eosinophilia.
Arefi M; Robledo C; Peñarrubia MJ; García de Coca A; Cordero M; Hernández-Rivas JM; García JL
Eur J Haematol; 2014 Nov; 93(5):422-8. PubMed ID: 24813417
[TBL] [Abstract][Full Text] [Related]
6. Issue Highlights - July 2019.
Cytometry B Clin Cytom; 2019 Jul; 96(4):253-255. PubMed ID: 31321907
[No Abstract] [Full Text] [Related]
7. Chromosome 8p11.2 translocations: prevalence, FISH analysis for FGFR1 and MYST3, and clinicopathologic correlates in a consecutive cohort of 13 cases from a single institution.
Patnaik MM; Gangat N; Knudson RA; Keefe JG; Hanson CA; Pardanani A; Ketterling RP; Tefferi A
Am J Hematol; 2010 Apr; 85(4):238-42. PubMed ID: 20143402
[TBL] [Abstract][Full Text] [Related]
8. The myeloproliferative neoplasms: insights into molecular pathogenesis and changes in WHO classification and criteria for diagnosis.
Anastasi J
Hematol Oncol Clin North Am; 2009 Aug; 23(4):693-708. PubMed ID: 19577165
[TBL] [Abstract][Full Text] [Related]
9. Jak2V617F driven myeloproliferative neoplasm occurs independently of interleukin-3 receptor beta common signaling.
Vu T; Austin R; Kuhn CP; Bruedigam C; Song A; Guignes S; Jacquelin S; Ramshaw HS; Hill GR; Lopez AF; Lane SW
Haematologica; 2016 Mar; 101(3):e77-80. PubMed ID: 26589916
[No Abstract] [Full Text] [Related]
10. Translocation (X;20) involving the inactive X chromosome in a patient with myeloproliferative disorder.
O'Reilly J; Crawford J; Uzaraga J; Cannell P
Cancer Genet Cytogenet; 2005 Apr; 158(1):81-3. PubMed ID: 15771910
[TBL] [Abstract][Full Text] [Related]
11. [A recurrent mutation of the JAK2 gene in chronic myeloproliferative disorders].
Berger R
Pathol Biol (Paris); 2006 May; 54(4):182-4. PubMed ID: 16084028
[No Abstract] [Full Text] [Related]
12. Genomic analysis of myeloproliferative neoplasms in chronic and acute phases.
Courtier F; Carbuccia N; Garnier S; Guille A; Adélaïde J; Cervera N; Gelsi-Boyer V; Mozziconacci MJ; Rey J; Vey N; Chaffanet M; Birnbaum D; Murati A
Haematologica; 2017 Jan; 102(1):e11-e14. PubMed ID: 27742771
[No Abstract] [Full Text] [Related]
13. Clinicopathologic and molecular characterization of myeloid neoplasms harboring isochromosome 17(q10).
Visconte V; Tabarroki A; Zhang L; Hasrouni E; Gerace C; Frum R; Ai J; Advani AS; Duong HK; Kalaycio M; Saunthararajah Y; Sekeres MA; His ED; Shetty S; Rogers HJ; Tiu RV
Am J Hematol; 2014 Aug; 89(8):862. PubMed ID: 24796269
[No Abstract] [Full Text] [Related]
14. Mutational analysis of bone marrow mesenchymal stromal cells in myeloid malignancies.
Fabiani E; Falconi G; Fianchi L; Guidi F; Bellesi S; Voso MT; Leone G; D'Alò F
Exp Hematol; 2014 Sep; 42(9):731-3. PubMed ID: 24796317
[No Abstract] [Full Text] [Related]
15. Focus on the epigenome in the myeloproliferative neoplasms.
Kim E; Abdel-Wahab O
Hematology Am Soc Hematol Educ Program; 2013; 2013():538-44. PubMed ID: 24319229
[TBL] [Abstract][Full Text] [Related]
16. LNK mutations in familial myeloproliferative neoplasms.
Rumi E; Harutyunyan AS; Pietra D; Feenstra JD; Cavalloni C; Roncoroni E; Casetti I; Bellini M; Milanesi C; Renna MC; Gotti M; Astori C; Kralovics R; Cazzola M
Blood; 2016 Jul; 128(1):144-5. PubMed ID: 27216218
[No Abstract] [Full Text] [Related]
17. Somatic mutations of calreticulin in myeloproliferative neoplasms.
Imai M; Araki M; Komatsu N
Int J Hematol; 2017 Jun; 105(6):743-747. PubMed ID: 28470469
[TBL] [Abstract][Full Text] [Related]
18. Absence of JAK2V617F mutation in Chinese deep vein thrombosis patients without myeloproliferative neoplasms.
Dong B; Zhang Y; Fu X; Wang G
Thromb Res; 2012 May; 129(5):664-5. PubMed ID: 22197451
[No Abstract] [Full Text] [Related]
19. Extramedullary T-lymphoid blast crisis of an ETV6/ABL1-positive myeloproliferative neoplasm with t(9;12)(q34;p13) and t(7;14)(p13;q11.2).
Yamamoto K; Yakushijin K; Nakamachi Y; Miyata Y; Sanada Y; Tanaka Y; Okamura A; Kawano S; Hayashi Y; Matsuoka H; Minami H
Ann Hematol; 2014 Aug; 93(8):1435-8. PubMed ID: 24318592
[No Abstract] [Full Text] [Related]
20. Next-generation sequencing-based panel testing for myeloid neoplasms.
Kuo FC; Dong F
Curr Hematol Malig Rep; 2015 Jun; 10(2):104-11. PubMed ID: 25933675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
